Avania, a leading global MedTech clinical research organization (CRO), has announced the appointment of Jason Monteleone as its new president and CEO, effective from September 2, 2024. Monteleone succeeds Sapna Hornyak, who had led the company since 2019. During Hornyak’s tenure, Avania significantly expanded its global presence and established itself as a strong player in the MedTech industry.
Monteleone brings over 25 years of experience in the CRO, medical device, and life sciences sectors to this role. He is recognized for his expertise in driving growth, operational excellence, and innovation. Prior to joining Avania, Monteleone held leadership positions in several prominent organizations, including serving as CEO of Clinipace from 2017 to 2021, where he oversaw a 65% revenue increase, ultimately leading to its acquisition by dMed in 2021. Earlier in his career, he held the position of chief financial officer at Theorem Clinical Research, where both revenue and staff numbers doubled under his leadership before the company was acquired by Chiltern International. Most recently, Monteleone was president of Ancillare, a global supplier of clinical trial equipment and ancillary supplies.
He is also actively involved in industry organizations, serving as a board member and audit chair for the Drug Information Association (DIA), a global organization fostering collaboration in drug, device, and diagnostic development. Monteleone’s diverse experience includes founding Pivotal Financial Consulting, where he advised investors and companies in clinical research on acquisitions and growth strategies.
His background in scaling businesses and delivering innovative solutions positions him well for Avania’s next phase of growth. Monteleone is tasked with continuing Avania’s strategic growth by deepening its expertise in key therapeutic areas such as cardiovascular, neurology, orthopedics, and aesthetics. He emphasized the importance of partnering with some of the world’s most innovative companies to develop life-changing products for patients. His focus will be on enhancing collaboration, innovation, and operational excellence across the board.
Todd Pope, chairman of Avania’s board, expressed his excitement about working closely with Monteleone, highlighting his vision for Avania to lead in MedTech innovation. Pope emphasized the company’s commitment to making a positive impact not only for its customers but also for its employees and the broader MedTech community.
Monteleone’s appointment comes at a crucial time for the MedTech industry, as demand for innovative medical devices and therapies continues to rise globally. His experience in leading CROs and scaling businesses positions Avania to meet these growing demands. With his leadership, Avania is expected to expand its market access, increase operational efficiency, and enhance its role in the global MedTech landscape.
Edouard Pillot, partner and co-head of Astorg Mid-Cap, Avania’s majority shareholder, welcomed Monteleone’s appointment, pointing to his impressive track record in driving growth and scaling businesses. Pillot noted that under Monteleone’s leadership, Avania is expected to create long-term value for its stakeholders while delivering distinct solutions to its customers.
Avania’s focus on innovation, operational excellence, and strategic partnerships will enable it to continue developing cutting-edge solutions for its customers. Monteleone’s vision aligns with Avania’s goal of maintaining its position as a leading MedTech CRO. As the company moves forward under new leadership, it is poised to expand its global footprint and further strengthen its presence in the MedTech and CRO industries.
